No data to show
XHKG
3692
Market cap18bUSD
Apr 03, Last price
23.70HKD
1D
-3.07%
1Q
42.26%
IPO
34.81%
Name
Hansoh Pharmaceutical Group Company Ltd
Chart & Performance
P/E
40.16
P/S
13.03
EPS
0.55
Div Yield, %
1.45%
Shrs. gr., 5y
1.08%
Rev. gr., 5y
5.52%
Revenues
10.10b
+7.69%
Net income
3.28b
+26.85%
CFO
3.12b
+13.69%
Dividend
Jul 03, 20250.1353 HKD/sh
Earnings
Aug 25, 2025
Profile
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 10,103,806 7.69% | 9,382,410 -5.56% | ||||||
Cost of revenue | 7,368,916 | 6,711,194 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 2,734,890 | 2,671,216 | ||||||
NOPBT Margin | 27.07% | 28.47% | ||||||
Operating Taxes | 488,652 | 364,681 | ||||||
Tax Rate | 17.87% | 13.65% | ||||||
NOPAT | 2,246,238 | 2,306,535 | ||||||
Net income | 3,277,503 26.85% | 2,583,747 -4.76% | ||||||
Dividends | (652,082) | (712,184) | ||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (76,878) | (140,093) | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 4,199,285 | 15,543 | ||||||
Long-term debt | 185,245 | 4,377,856 | ||||||
Deferred revenue | 3,932,081 | |||||||
Other long-term liabilities | 277,007 | (4,282,742) | ||||||
Net debt | (18,734,867) | (17,890,840) | ||||||
| Cash flow | ||||||||
Cash from operating activities | 3,116,468 | 2,741,205 | ||||||
CAPEX | (219,598) | (272,821) | ||||||
Cash from investing activities | 1,073,972 | (5,935,073) | ||||||
Cash from financing activities | (753,695) | (818,144) | ||||||
FCF | 4,994,694 | 1,771,861 | ||||||
| Balance | ||||||||
Cash | 24,857,066 | 21,630,589 | ||||||
Long term investments | (1,737,669) | 653,650 | ||||||
Excess cash | 22,614,207 | 21,815,118 | ||||||
Stockholders' equity | 11,807,880 | 8,780,342 | ||||||
Invested Capital | 18,567,635 | 18,115,851 | ||||||
ROIC | 12.25% | 13.24% | ||||||
ROCE | 9.00% | 9.80% | ||||||
| EV | ||||||||
Common stock shares outstanding | 6,019,650 | 5,929,483 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 3,101,271 | 3,015,818 | ||||||
EV/EBITDA | ||||||||
Interest | 66,679 | 58,142 | ||||||
Interest/NOPBT | 2.44% | 2.18% | ||||||